Andjelic, Bosko (6507067141)Bosko (6507067141)AndjelicMihaljevic, Biljana (6701325767)Biljana (6701325767)MihaljevicTodorovic, Milena (23010544100)Milena (23010544100)TodorovicBila, Jelena (57208312102)Jelena (57208312102)BilaJakovic, Ljubomir (21742748500)Ljubomir (21742748500)JakovicJovanovic, Maja Perunicic (57210906777)Maja Perunicic (57210906777)Jovanovic2025-07-022025-07-022012https://doi.org/10.1097/PAI.0b013e318223ef29https://www.scopus.com/inward/record.uri?eid=2-s2.0-83655167341&doi=10.1097%2fPAI.0b013e318223ef29&partnerID=40&md5=4d634deda618beb922fcd1f7bc162da5https://remedy.med.bg.ac.rs/handle/123456789/14030The clinical course of patients with follicular lymphoma is variable from a slowly progressive disease to a progressive disease with a survival time of approximately 1 year. Many prognostic models have been suggested to identify high-risk patients. Recent gene profiling analysis showed that the clinical behavior of follicular lymphoma is determined by the properties of the nonmalignant tumor microenvironment. We investigated the role of lymphoma-associated macrophages (LAMs) in tumor tissue in patients with newly diagnosed follicular lymphoma. The LAM was determined immunohistochemically in lymph node tissue sections by anti-CD68 PG-M1 and analyzed through high-power field (HPF) magnification intrafollicularly (IF) and extrafollicularly. In our study, the patients who had an IF LAM count equal to or more than 10/HPF had significantly shorter overall survival (P=0.018) and 3 years of progression-free survival (P=0.034) compared with patients with <10 LAM/HPF. Multivariate analysis indicated that IF LAM/HPF ≥10 and Eastern Cooperative Oncology Group performance status >1 are independent prognostic factors for a poor outcome. © 2011 by Lippincott Williams & Wilkins.follicular lymphomamacrophagesprognosis